EZH2 and hepatocellular carcinoma: Later studies with more specific EZH2 inhibitors showed that in hepatocellular carcinoma the combination of 5-azadeoxycitidine with the EZH2 inhibitor GSK126 increased expression of neoantigens, increased tumor-infiltrating lymphocytes and reduced cell growth (32, 33).